• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy.

作者信息

De Lena M, Brambilla C, Valagussa P, Bonadonna G

出版信息

Cancer Chemother Pharmacol. 1979;2(3):175-80. doi: 10.1007/BF00258291.

DOI:10.1007/BF00258291
PMID:455571
Abstract
摘要

相似文献

1
High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy.
Cancer Chemother Pharmacol. 1979;2(3):175-80. doi: 10.1007/BF00258291.
2
An evaluation of high-dose medroxyprogesterone acetate (MPA) therapy in women with advanced breast cancer.对晚期乳腺癌女性患者进行大剂量醋酸甲羟孕酮（MPA）治疗的评估。
Br J Cancer. 1984 Sep;50(3):363-6. doi: 10.1038/bjc.1984.184.
3
[High-dose gestagen therapy with medroxyprogesterone acetate in metastasizing breast carcinoma].[醋酸甲羟孕酮高剂量孕激素疗法用于转移性乳腺癌]
Med Welt. 1983 Mar 25;34(12):378-82.
4
[High dose medroxyprogesterone acetate in metastatic breast cancer. Comparative clinical, pharmacokinetic and pharmacodynamic data of different forms of administration].[大剂量醋酸甲羟孕酮治疗转移性乳腺癌。不同给药方式的临床、药代动力学和药效学对比数据]
Onkologie. 1982 Aug;5 Suppl:13-6.
5
Pharmacoclinical data on high dose medroxyprogesterone acetate in advanced breast cancer.醋酸甲羟孕酮高剂量用于晚期乳腺癌的药物临床数据。
Breast Cancer Res Treat. 1986;8(2):161-3. doi: 10.1007/BF01807705.
6
Hormone therapy in advanced breast cancer: high dose medroxyprogesterone acetate (MAP) vs tamoxifen (TMX). Preliminary results.晚期乳腺癌的激素治疗：大剂量醋酸甲羟孕酮（MAP）与他莫昔芬（TMX）对比。初步结果。
Eur J Cancer (1965). 1980;Suppl 1:93-8.
7
Oral plus intramuscular medroxyprogesterone acetate (high dose Farlutal) in advanced breast cancer.
Southeast Asian J Trop Med Public Health. 1985 Dec;16(4):634-7.
8
[Estrogen antagonists and inhibitors in hormone therapy of breast cancer].[雌激素拮抗剂与抑制剂在乳腺癌激素治疗中的应用]
Vopr Onkol. 1989;35(7):771-8.
9
[Evaluation of the results of treatment with medroxyprogesterone acetate (MPA) of patients with advanced breast cancer].[醋酸甲羟孕酮（MPA）治疗晚期乳腺癌患者的疗效评估]
Nowotwory. 1985 Jul-Sep;35(3):243-8.
10
Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.低剂量与高剂量醋酸甲羟孕酮用于绝经后晚期乳腺癌患者诱导治疗的随机试验
J Clin Oncol. 1984 May;2(5):414-9. doi: 10.1200/JCO.1984.2.5.414.

引用本文的文献

1
Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling.孕激素受体亚型、激动剂和拮抗剂对雌激素信号传导进行差异性重编程。
Oncotarget. 2017 Sep 28;9(4):4282-4300. doi: 10.18632/oncotarget.21378. eCollection 2018 Jan 12.
2
Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routes.
Cancer Chemother Pharmacol. 1980;4(4):267-9. doi: 10.1007/BF00255272.
3
Adrenal suppression by oral high-dose medroxyprogesterone acetate in breast cancer patients.口服高剂量醋酸甲羟孕酮对乳腺癌患者肾上腺功能的抑制作用。

本文引用的文献

1
THE VALUE OF NORETHISTERONE ACETATE IN THE TREATMENT OF ADVANCED CARCINOMA OF THE BREAST.醋酸炔诺酮在晚期乳腺癌治疗中的价值
Clin Radiol. 1963 Oct;14:445-6. doi: 10.1016/s0009-9260(63)80037-9.
2
Progestin therapy of breast cancer: comparison of agents.乳腺癌的孕激素治疗：药物比较
Br Med J. 1967 Aug 5;3(5561):338-41. doi: 10.1136/bmj.3.5561.338.
3
Therapy by progestational agents in advanced breast cancer.晚期乳腺癌的孕激素治疗
Cancer Chemother Pharmacol. 1984;12(2):83-6. doi: 10.1007/BF00254594.
4
Current status of high dose progestin treatment in advanced breast cancer.大剂量孕激素治疗晚期乳腺癌的现状
Breast Cancer Res Treat. 1983;3(2):231-5. doi: 10.1007/BF01803566.
5
Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patients.
Cancer Chemother Pharmacol. 1983;11(1):19-22. doi: 10.1007/BF00257410.
6
[High dose medroxyprogesteroneacetate in metastasizing breast cancer: correlations between course of the disease and hormone profiles].[大剂量醋酸甲羟孕酮治疗转移性乳腺癌：疾病进程与激素谱之间的相关性]
Klin Wochenschr. 1983 Jun 1;61(11):553-60. doi: 10.1007/BF01486845.
7
Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer. A preliminary report of clinical and experimental studies.口服大剂量醋酸甲羟孕酮治疗晚期乳腺癌：临床与实验研究的初步报告
Breast Cancer Res Treat. 1981;1(2):125-30. doi: 10.1007/BF01805865.
8
Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone acetate in clinical oncology.醋酸甲羟孕酮临床肿瘤学给药方案选择的药代动力学方法
Cancer Chemother Pharmacol. 1982;8(2):151-6. doi: 10.1007/BF00255475.
9
The pharmacokinetics of high-dose medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancer.高剂量醋酸甲羟孕酮（MPA）治疗晚期乳腺癌的药代动力学
Cancer Chemother Pharmacol. 1982;8(1):77-81. doi: 10.1007/BF00292875.
10
Weekly low dose doxorubicin monotherapy in metastatic breast cancer resistant to previous hormonal and cytostatic treatment.每周低剂量阿霉素单药治疗对先前激素和细胞抑制治疗耐药的转移性乳腺癌。
Breast Cancer Res Treat. 1985;6(1):89-93. doi: 10.1007/BF01806014.
Med J Aust. 1966 Feb 26;1(9):331-4. doi: 10.5694/j.1326-5377.1966.tb72345.x.
4
Clinical trial of delta-1-testololactone (NSC 23759), medroxy progesterone acetate (NSC 26386) and oxylone acetate (NSC 47438) in advanced female mammary cancer. A report of the cooperative breast cancer group.δ-1-睾丸内酯（NSC 23759）、醋酸甲羟孕酮（NSC 26386）和醋酸奥昔酮（NSC 47438）用于晚期女性乳腺癌的临床试验。合作乳腺癌研究组报告
Cancer. 1969 Jan;23(1):109-12. doi: 10.1002/1097-0142(196901)23:1<109::aid-cncr2820230112>3.0.co;2-1.
5
Hormonal therapy in cancer of the breast. XXIV. Effect of corticosterone or medroxyprogesterone acetate on clinical course and hormonal excretion.乳腺癌的激素治疗。二十四。皮质酮或醋酸甲羟孕酮对临床病程和激素排泄的影响。
Cancer. 1967 Oct;20(10):1673-8. doi: 10.1002/1097-0142(196710)20:10<1673::aid-cncr2820201016>3.0.co;2-6.
6
A clinical trial of megestrol acetate in advanced breast cancer.醋酸甲地孕酮治疗晚期乳腺癌的临床试验。
Cancer. 1974 Apr;33(4):907-10. doi: 10.1002/1097-0142(197404)33:4<907::aid-cncr2820330403>3.0.co;2-y.
7
Norethisterone acetate (SH420) in advanced breast cancer.醋酸炔诺酮（SH420）用于晚期乳腺癌
Cancer. 1973 Dec;32(6):1317-20. doi: 10.1002/1097-0142(197312)32:6<1317::aid-cncr2820320604>3.0.co;2-a.
8
Treatment of breast cancer with medroxyprogesterone acetate.醋酸甲羟孕酮治疗乳腺癌
Ann Intern Med. 1968 Feb;68(2):328-37. doi: 10.7326/0003-4819-68-2-328.
9
Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.醋酸甲羟孕酮（NSC - 26386）作为绝经后女性转移性乳腺癌二线激素治疗的疗效
Cancer Treat Rep. 1976 Mar;60(3):251-3.
10
Norethisterone acetate in the treatment of advanced breast cancer.醋酸炔诺酮治疗晚期乳腺癌。
Eur J Cancer (1965). 1976 Jul;12(7):563-5. doi: 10.1016/0014-2964(76)90163-8.